Ocular complications in pediatric nephrotic syndrome treated with corticosteroids

Pub Date : 2024-02-06 DOI:10.14238/pi64.1.2024.1-9
Yulia Margareta L. Toruan, Partini Pudjihastuti Trihono, Rita Sita Sitorus, Pramita Dwipoerwantoro
{"title":"Ocular complications in pediatric nephrotic syndrome treated with corticosteroids","authors":"Yulia Margareta L. Toruan, Partini Pudjihastuti Trihono, Rita Sita Sitorus, Pramita Dwipoerwantoro","doi":"10.14238/pi64.1.2024.1-9","DOIUrl":null,"url":null,"abstract":"Background Posterior subcapsular cataracts (PSC) and raised intraocular pressure (IOP) are the most common ocular complications of oral steroid administration, particularly following long-term use or treatment with high doses. \nObjective To evaluate the association between cumulative steroid dose and duration of treatment with the occurrence of PSC and raised IOP, as well as its associated factors in children with idiopatic nephrotic syndrome (INS). \nMethods This cross-sectional study included children aged 4–18 years with INS who received oral steroid therapy for at least six consecutive months. Patients underwent complete eye examinations by an ophthalmologist to evaluate their visual acuity as well as the occurrence of PSC and/or raised IOP. Results Of 92 subjects, 19.6% had PSC, 12% had raised IOP, and one had a best corrected visual acuity (BCVA) of <6/20. The median cumulative steroid dose was 12,161 (range 1,795–81,398) mg and median treatment duration was 23 (range 6–84) months. There were significant positive associations between cumulative steroid dose as well as treatment duration and the occurrence of PSC, with cut-off points of 11,475 mg and 24 months, respectively, as determined by receiver operator characteristic (ROC) curves. Females were four times more likely to have PSC compared to males (PR 4; 95%CI 1.57 to 13.38; P=0.001). Cumulative steroid dose and duration of treatment were not associated with raised IOP. \nConclusion Cumulative steroid dose of 11,475 mg or higher and/or duration of steroid therapy of 24 months of more were significantly associated with the occurrence of PSC, but not with raised IOP.","PeriodicalId":0,"journal":{"name":"","volume":"38 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14238/pi64.1.2024.1-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background Posterior subcapsular cataracts (PSC) and raised intraocular pressure (IOP) are the most common ocular complications of oral steroid administration, particularly following long-term use or treatment with high doses. Objective To evaluate the association between cumulative steroid dose and duration of treatment with the occurrence of PSC and raised IOP, as well as its associated factors in children with idiopatic nephrotic syndrome (INS). Methods This cross-sectional study included children aged 4–18 years with INS who received oral steroid therapy for at least six consecutive months. Patients underwent complete eye examinations by an ophthalmologist to evaluate their visual acuity as well as the occurrence of PSC and/or raised IOP. Results Of 92 subjects, 19.6% had PSC, 12% had raised IOP, and one had a best corrected visual acuity (BCVA) of <6/20. The median cumulative steroid dose was 12,161 (range 1,795–81,398) mg and median treatment duration was 23 (range 6–84) months. There were significant positive associations between cumulative steroid dose as well as treatment duration and the occurrence of PSC, with cut-off points of 11,475 mg and 24 months, respectively, as determined by receiver operator characteristic (ROC) curves. Females were four times more likely to have PSC compared to males (PR 4; 95%CI 1.57 to 13.38; P=0.001). Cumulative steroid dose and duration of treatment were not associated with raised IOP. Conclusion Cumulative steroid dose of 11,475 mg or higher and/or duration of steroid therapy of 24 months of more were significantly associated with the occurrence of PSC, but not with raised IOP.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
使用皮质类固醇治疗小儿肾病综合征的眼部并发症
背景 后囊下白内障(PSC)和眼压升高(IOP)是口服类固醇最常见的眼部并发症,尤其是在长期使用或大剂量治疗后。目的 评估特发性肾病综合征(INS)患儿的类固醇累积剂量和治疗持续时间与 PSC 和眼压升高之间的关系及其相关因素。方法 该横断面研究纳入了年龄在 4-18 岁、至少连续六个月接受口服类固醇治疗的 INS 儿童。患者接受眼科医生的全面眼部检查,以评估视力以及 PSC 和/或眼压升高的发生情况。结果 在92名受试者中,19.6%患有PSC,12%眼压升高,其中一人的最佳矫正视力(BCVA)小于6/20。类固醇累积剂量中位数为 12,161 毫克(范围为 1,795-81,398 毫克),治疗时间中位数为 23 个月(范围为 6-84 个月)。根据接收器运算特征曲线(ROC),累积类固醇剂量和治疗时间与 PSC 的发生之间存在明显的正相关,临界点分别为 11,475 毫克和 24 个月。女性发生 PSC 的几率是男性的四倍(PR 4;95%CI 1.57 至 13.38;P=0.001)。类固醇累积剂量和治疗时间与眼压升高无关。结论 类固醇累积剂量达到或超过 11,475 毫克和/或类固醇治疗持续时间超过 24 个月与 PSC 的发生显著相关,但与眼压升高无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1